| Treatment of adenovirus infections in the immunocompromised host. | |
| | |
MedLine Citation:
|
PMID: 15248091 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Adenovirus infections are increasing as causes of morbidity and mortality in severely immunocompromised patients. The currently available antiviral agents, ribavirin and cidofovir, have yielded mixed results in case reports and small case series. Similar to cytomegalovirus disease, established adenovirus disease is often difficult to treat. Therapy may yield poor results, even when effective antiviral drugs are used. New strategies, including pre-emptive therapy, should be tested in prospective, clinical trials. New agents and adoptive transfer of specific T-cells to adenovirus might improve the current situation. |
| | |
Authors:
|
P Ljungman |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2004-07-10 |
Journal Detail:
|
Title: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology Volume: 23 ISSN: 0934-9723 ISO Abbreviation: Eur. J. Clin. Microbiol. Infect. Dis. Publication Date: 2004 Aug |
Date Detail:
|
Created Date: 2004-08-23 Completed Date: 2004-10-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8804297 Medline TA: Eur J Clin Microbiol Infect Dis Country: Germany |
Other Details:
|
Languages: eng Pagination: 583-8 Citation Subset: IM |
Affiliation:
|
Department of Haematology, Karolinska University Hospital/Huddinge, 14186 Stockholm, Sweden. per.ljungman@medhs.ki.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoviridae Infections
/
drug therapy*,
epidemiology*,
immunology Antiviral Agents / therapeutic use* Clinical Trials as Topic Cytosine / analogs & derivatives*, therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Female Ganciclovir / therapeutic use Hematopoietic Stem Cell Transplantation Humans Immunocompromised Host* Male Organ Transplantation Organophosphorus Compounds / therapeutic use Phosphonic Acids* Prognosis Ribavirin / therapeutic use Severity of Illness Index Transplantation Immunology Treatment Outcome Vidarabine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Organophosphorus Compounds; 0/Phosphonic Acids; 113852-37-2/cidofovir; 36791-04-5/Ribavirin; 5536-17-4/Vidarabine; 71-30-7/Cytosine; 82410-32-0/Ganciclovir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ram horn peptone as a source of citric acid production by Aspergillus niger, with a process.
Next Document: A new confirmatory Neisseria gonorrhoeae real-time PCR assay targeting the porA pseudogene.